Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775 | 0.90 | MEN1 (0.42) | NR1H4TDP1MEN1KMT2AHTT | |
| SCHEMBL2153555 | 0.88 | MEN1 (0.50) | NR1H4TDP1MEN1KMT2AHTT | |
| SCHEMBL2153552 | 0.88 | MEN1 (0.50) | NR1H4TDP1MEN1KMT2AHTT | |
| SCHEMBL26133 | 0.82 | RECQL (0.42) | NR1H4TDP1MEN1KMT2AHTT | |
| SCHEMBL3639263 | 0.78 | HTT (0.47) | TDP1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL2153548 | 0.78 | HTT (0.51) | NR1H4TDP1MEN1KMT2AHTT | |
| SCHEMBL8190236 | 0.78 | MEN1 (0.44) | TDP1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL28193618 | 0.77 | HSD17B10 (0.59) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL3135666 | 0.77 | ALDH1A1 (0.55) | TDP1MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL3135676 | 0.77 | ALDH1A1 (0.55) | TDP1MEN1KMT2AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9238616-B2 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8367722-B2 | Methods of using prodrugs of pregabalin | XENOPORT, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367711-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-20 | — | — | US | disclosed |
| US-8252825-B2 | Angiotensin II receptor antagonists | NICOX (IT) | 2012-08-28 | — | — | US | disclosed |
| US-8207208-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| CN-102482256-A | N-substituted cyclic amino derivatives | DAINIPPON SUMITOMO PHARMA CO | 2012-05-30 | — | — | CN | disclosed |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2004-01-08 | — | — | US | disclosed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | disclosed |
| EP-1343805-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | Xenoport, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002028881-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| US-5684018-A | Acyloxyisopropyl carbamates as prodrugs for amine drugs | MERCK & CO., INC. (US) | 1997-11-04 | — | — | US | disclosed |
| WO-1996018605-A1 | ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | NR1H4 849/4885TDP1 1112/4885MEN1 2201/4885 |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | NR1H4 849/4885TDP1 1112/4885MEN1 2201/4885 |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | NR1H4 849/4885TDP1 1112/4885MEN1 2201/4885 |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | NR1H4 849/4885TDP1 1112/4885MEN1 2201/4885 |
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | SLC10A2, SLC10A1, ABCB11 | NR1H4 4/4885TDP1 4158/4885MEN1 1245/4885 |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | NR1H4 194/4885TDP1 4705/4885MEN1 1614/4885 |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | NR1H4 849/4885TDP1 1112/4885MEN1 2201/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | NR1H4 849/4885TDP1 1112/4885MEN1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.